# A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

> **NCT04522323** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **MedImmune LLC** · enrollment: 67 (actual)

## Conditions studied

- Advanced Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** MEDI5752
- **DRUG:** Axitinib
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT04522323
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-05
- **Primary completion:** 2025-09-26
- **Final completion:** 2025-09-26
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2025-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04522323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04522323, "A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04522323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*